Cell Therapeutics Inc., of Seattle, agreed to sell up to $25 million in shares of its Series 8 nonconvertible preferred stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25 million in shares of its Series 9 convertible preferred stock in a registered offering to an unnamed life sciences institutional investor.